UNSPSC 51372037: Morphine sulfate anhydrous

This classification denotes an opiate with the molecular formula 2C17H19NO3.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DY70C97N30, chemically known as morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl, (5.alpha.,6.alpha.)-, sulfate (2:1) (salt), but more generally known as morphine sulfate anhydrous, which bears US NIH Compound Identifier 5359250. European Medicines Agency schedules morphine sulfate anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03332MIG.

UNSPSC 51372037 Morphine sulfate anhydrous is a Commodity code that in practice captures pharmaceutical procurement by state and local health agencies, though the single recent opportunity in the dataset involves naloxone and drug deactivation systems rather than morphine sulfate directly. State and local governments buy controlled pharmaceuticals and related medical supplies through this code to support community health, emergency response, and public health initiatives. Issuing bodies include county health departments and community health agencies, with Seminole County, Florida appearing as a recent buyer.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford and a response deadline of July 26, 2023. The solicitation required electronic bid submission through the county's e-Procurement Portal, unit pricing for each line item, drug-free workplace and E-Verify compliance, and workers' compensation and liability insurance. The contract included a two-year initial term with a one-year renewal option and was potentially funded through FEMA, introducing federal compliance requirements. The code shows limited recent activity in the dataset, and the single example involves public health emergency response rather than pharmaceutical procurement in its narrowest sense.